LAAO and the Watchman FLX; HF Care in Private Equity Hospitals; Long-term Outcomes in TR and Mitral Valve-in-Valve Replacement

In this week’s View, Dr. Eagle looks at frailty status and increased risk of mortality in patients who undergo percutaneous coronary intervention (PCI). He then discusses the timely treatment and delays in treatment of ST-segment elevation myocardial infarction (STEMI) that are associated with worse outcomes. Finally, Dr. Eagle explores new insights on arterial events associated with heritable thoracic aortic disease and the relative risk in patients with pathogenic variants, as well as the prevalence, characteristics, and clinical outcomes of arterial aneurysms in Loeys-Dietz Syndrome.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the lower risk of major adverse events in patients with left atrial appendage occlusion (LAAO) using the Watchman 2.4 device. He then discusses the impact of heart failure (HF) care in private equity hospitals in the United States. Finally, Dr. Eagle explores the long-term outcomes of patients with tricuspid regurgitation (TR) undergoing mitral valve-in-valve (MViV) replacement.   Subscribe to Eagle’s Eye View    

In this week’s View, Dr. Eagle looks at chronic marijuana smoking and THC-edible use and its impairment of endothelial function. He then discusses the cardiovascular (CV) and bleeding effects of aspirin versus clopidogrel in patients with acute coronary syndromes. Finally, Dr. Eagle explores the importance of addressing mental health symptoms in survivors of sudden cardiac arrest (SCA) who experience shocks from an implantable cardioverter-defibrillator (ICD).   Subscribe to Eagle’s Eye View    

In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the results of the ORBITA-2 Trial and its use in stress echocardiography before PCI. He then discusses the proportion of patients achieving blood pressure (BP) control plateaus despite increasing medication prescriptions. Finally, Dr. Eagle explores the use of rapid initiation and titration in guideline-recommended medical therapy (GRMT) in patients with heart failure with reduced ejection fraction (HFrEF).   Subscribe to Eagle’s Eye View    

In this week’s View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation (AFib).  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the echocardiographic outcomes at five years.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores OCEANIC-AF, a study that analyzes the differences in outcomes in patients with and without prior use of oral anti-coagulants (OACs).   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including:   Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up   SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI)  DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI)  STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes  RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus   API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE)    Subscribe to Eagle’s Eye View